Trend
DailyDowntrend (confirmed)
4 hourLeaning Bullish
1 hourStrong Bullish
15 minSymmetric Triangle
5 minStrong Bullish
Daily trend turns up above $2.25
Key levels
Resistance$1.77
Resistance$1.50
Latest news & SEC filings
No headlines in the last 90 days.
Skye Bioscience develops experimental medicines for obesity, excess weight, and metabolic conditions. Its main drug candidate, nimacimab, is an antibody designed to act on the CB1 receptor while staying out of the brain. The company is studying nimacimab both on its own and alongside incretin-based drugs such as semaglutide.
Based on the company's 10-K filed Mar 10, 2026.
Nasdaq · Healthcare
SEPT Low Target
$0.00
SEPT Mid Target
$0.00
SEPT High Target
$0.00
Analyst Consensus
$0.00
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for SKYE.
Start Free Trial →Valuation Verdict
N/A
Methods Used
N/A
Fair Value
$N/A
15
Moat Score
NONE
1/9
Piotroski Score
-11.5
Altman Z-Score
Insider Signal
SELLING
0 buys / 12 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
MEDIUM
Signal: NEUTRAL
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Schwab Andrew J. | director 10% owner | Sale | 114,851 | $185K | Sep 23, 2026 |
| Schwab Andrew J. | director 10% owner | Sale | 4,528 | $7K | Sep 23, 2026 |
| 5AM Partners VII, LLC | 10% owner | Sale | 114,851 | $185K | Sep 23, 2026 |
| 5AM Partners VII, LLC | 10% owner | Sale | 4,528 | $7K | Sep 23, 2026 |
| Schwab Andrew J. | director 10% owner | Sale | 27,612 | $46K | Sep 22, 2026 |
| Schwab Andrew J. | director 10% owner | Sale | 1,088 | $2K | Sep 22, 2026 |
| 5AM Partners VII, LLC | 10% owner | Sale | 27,612 | $46K | Sep 22, 2026 |
| 5AM Partners VII, LLC | 10% owner | Sale | 1,088 | $2K | Sep 22, 2026 |
| Schwab Andrew J. | director 10% owner | Sale | 32,607 | $62K | Sep 16, 2026 |
| Schwab Andrew J. | director 10% owner | Sale | 1,285 | $2K | Sep 16, 2026 |
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
-93.15%
FCF Growth YoY
-60.5%
Revenue Trend
UNKNOWN
SEPT Investing tracks real-time dark pool institutional trades for SKYE, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 14:31:57 | $0.86 | 2,005 | $$2K | SELL |
| 13:37:42 | $0.98 | 1,845 | $$2K | BUY |
| 21:31:00 | $0.94 | 1,000 | $$937 | BUY |
| 20:57:00 | $0.91 | 4,800 | $$4K | SELL |
| 20:39:38 | $0.87 | 1,000 | $$872 | SELL |
5 dark pool trades shown · $$10K preview volume
Real-time institutional flow, block trades, and net positioning
SEPT's Trading AI has generated a free, downloadable PDF research report for Skye Bioscience, Inc. (SKYE) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →Skye Bioscience, Inc. (SKYE) is at $0.82, down 10.73% (-$0.10) at the Nov 12, 2026 close.
Analyst ratings for SKYE: 2 Buy, 2 Hold, 0 Sell — consensus Buy.
SKYE last reported on Aug 14, 2026: EPS -$2.16 vs -$2.04 expected — a miss of 5.9%.
SKYE does not currently pay a dividend.
Resistance: $1.50, $1.77, $1.95.
Insider activity: SELLING, 0 buys and 12 sells in the last 90 days.